Public service announcements about drug use or other public health problems often fall short, public health marketing experts say, because they incite people’s worst fears rather than giving people solutions.
President Donald Trump made substantial changes to the nation’s health care system using executive branch authority. But reversing policies that Democrats oppose would take time and personnel resources, competing with other priorities of the new administration.
Most private insurance will be required to cover drugs, like Truvada, that offer protection against HIV infection, without making plan members share the cost.
While many private insurers cap what members pay in health costs, Medicare does not. Democrats and Republicans in Congress have proposed annual limits ranging from $2,000 to $3,100. But there’s disagreement about how to pay for that cost cap.
COVID-19’s “long haulers” — patients with lingering effects of the disease — have joined the ranks of Americans with preexisting conditions. For those shopping for health coverage on the individual market, here’s help navigating an uncharted insurance landscape.
A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients’ financial realities are only widening amid the economic crisis of the COVID pandemic.
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.